LEGN earnings: next report 2026-08-10, real EPS beat/miss history, analyst consensus Buy, P/E -17.30. Updated 2026-07-23.
Legend Biotech (LEGN) Research Hub
Legend Biotech (LEGN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 18.64 USD (-6.38%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -17.30, market cap 4.30B. This hub links to the full technical, earnings and options research available for LEGN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 18.64 USD (-6.38%) |
| 52-week range | 18.33 USD – 36.18 USD |
| Trend regime | Range |
| 14-day RSI | 41.7 (Bearish) |
| Trailing P/E | -17.30 |
| Market cap | 4.30B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for LEGN
Covered Call on LEGN: how it works, illustrative setup around the real 18.64 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on LEGN: how it works, illustrative setup around the real 18.64 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on LEGN: how it works, illustrative setup around the real 18.64 USD price, max profit/loss, breakeven and when to use it. Educational.
LEGN technical analysis: range, last 18.64 USD, RSI 41.7, 52w range 18.33 USD–36.18 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is LEGN in?
Legend Biotech (LEGN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is LEGN in an uptrend or downtrend?
As of 2026-09-11, LEGN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is LEGN's trailing P/E ratio?
LEGN's trailing P/E is -17.30, with a market cap of 4.30B. See the earnings research page for full valuation detail.
When does LEGN next report earnings?
LEGN is next scheduled to report earnings on 2026-08-10, with a consensus EPS estimate of 0.0551 USD.